SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity Against Chronic Eosinophilic Leukemia
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity against Chronic Eosinophilic Leukemia. ASH 2013. Abstract | Poster
SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Inhibits Plasmacytoid Dendritic Cell (pDC)-Induced Myeloma Cell Growth and Overcomes Drug Resistance
SL-401, A Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Inhibits Plasmacytoid Dendritic Cell (pDC)-induced Myeloma Cell Growth and Overcomes Drug Resistance. ASH 2013. Abstract | Poster
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor on Cancer Stem Cells and Tumor Bulk, Has Broad Clinical Activity and Tolerability as a Single Agent in Patients With Advanced Hematological Malignancies
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor on Cancer Stem Cells and Tumor Bulk, Has Broad Clinical Activity and Tolerability as a Single Agent in Patients with Advanced Hematological Malignancies. ASCO 2013. Abstract | Poster
Clinical and Preclinical Activity of SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor on Cancer Stem Cells and Tumor Bulk of Hematologic Malignancies, Against Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Clinical and Preclinical Activity of SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor on Cancer Stem Cells and Tumor Bulk of Hematologic Malignancies, Against Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). ASCO 2013. Abstract | Poster
A Novel Agent SL-401 Targeting Interleukin-3 (IL-3)-Receptor Blocks Plasmacytoid Dendritic Cell (pDC)-Induced Myeloma Cell Growth and Overcomes Drug Resistance
A Novel Agent SL-401 Targeting Interleukin-3 (IL-3)-Receptor Blocks Plasmacytoid Dendritic Cell (pDC)-induced Myeloma Cell Growth and Overcomes Drug Resistance. ASCO 2013. Abstract | Poster
Peptide Vaccine Therapy for Childhood Gliomas: Interim Results of a Pilot Study
Peptide vaccine therapy for childhood gliomas: interim results of a pilot study. AACR 2012. Abstract | Poster
Anti-Leukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody-Conjugate in Acute Myeloid Leukemia
Anti-leukemia efficacy and mechanisms of action of SL-101, a novel anti-CD123 antibody-conjugate in acute myeloid leukemia. ASH 2014. Poster
SL-101, a Novel Monoclonal Antibody-Conjugate That Targets Interleukin-3 Receptor Alpha (CD123), Possesses Preclinical Anti-Tumor Activity Against Hodgkin's Lymphoma
SL-101, A Novel Monoclonal Antibody-Conjugate That Targets Interleukin-3 Receptor Alpha (CD123), Possesses Preclinical Anti-Tumor Activity Against Hodgkin’s Lymphoma. ASH 2012. Abstract | Poster
SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML. ASH 2012.
SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML. ASH 2012. Abstract | Poster
A Pilot Study of Peptide-Based Vaccines in Combination With Poly ICLC in Patients With WHO Grade 2 Low-Grade Glioma
A pilot study of peptide-based vaccines in combination with poly ICLC in patients with WHO grade 2 low-grade glioma. AACR 2012. Abstract